Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 21

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 21
---
 the maximum number of shares of common stock issued or issuable pursuant to Series D Certificate of Designations, determined
as if the outstanding Series D Preferred Stock were converted in full (without regard to any limitations on conversion contained therein
solely for the purpose of such calculation) at a conversion price calculated as of the trading day immediately preceding the date this
registration statement was initially filed with the SEC. Because the alternate conversion price and conversion price of the Series D Preferred
Stock may be adjusted, the number of shares that will actually be issued may be more or less than the number of shares being offered by
this prospectus. Notwithstanding the foregoing, because the Alternate Conversion Price changes daily, we have elected to register the
number of shares of Common Stock equal to 300% of the maximum number of Common Stock issuable upon conversion of the Series D Preferred
Stock at the Floor Price. The fourth column assumes the sale of all of the shares offered by the selling stockholders pursuant to this
prospectus.

Under the terms of the Series D Preferred Stock,
certain selling stockholders may not convert the Series D Preferred Stock to the extent (but only to the extent) such selling stockholder
or any of its affiliates would beneficially own a number of shares of our common stock which would exceed 4.99% (the “Maximum Percentage”)
of the outstanding shares of the Company. The number of shares in the second column reflects these limitations. The selling stockholders
may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

We may amend or supplement this prospectus from
time to time in the future to update or change these Selling Stockholders and the securities that may be resold.

Except as set forth in the footnotes below, the
business address of each Selling Stockholder is c/o CERo Therapeutics Holdings, Inc., 201 Haskins Way, Suite 230, South San Francisco,
CA.

<div align='center'>8</div>

|                                                  |     | Number                   
 of Shares of             
 Common Stock             
 Beneficially Owned Prior 
 to Offering (1)          |        |     |         |      |   |     | Maximum Number of 
 Shares of Common  
 Stock Registered  
 Pursuant to the   
 Registration      |           |     | Number             
 of Shares of       
 Common Stock Owned 
 After Offering(3)  |       |     |         |   |
| Name of Selling Stockholder                      |     | Number                   |        |